Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer

NCT02874664 is registered in ClinicalTrials.gov with Stemcentrx as lead sponsor.

NCT NCT02874664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02874664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Intensive QT/QTc Study to Investigate the Effects of Rovalpituzumab Tesirine on Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer
Lead sponsor
Stemcentrx
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2016
Completion date
September 12, 2018
Enrollment
46 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

small cell lung carcinoma